The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

@article{Vollenweider2010TheNO,
  title={The neurobiology of psychedelic drugs: implications for the treatment of mood disorders},
  author={F. Vollenweider and M. Kometer},
  journal={Nature Reviews Neuroscience},
  year={2010},
  volume={11},
  pages={642-651}
}
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and… Expand
Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.
TLDR
Evidence of the use of psychedelics as adjunct therapy for a number of psychiatric and addictive disorders is reviewed, and psychedelics appear to have efficacy in treating depression and alcohol-use disorders. Expand
Animal models of serotonergic psychedelics.
TLDR
The behavioral effects induced by psychedelic drugs in rodent models are reviewed, the translational potential of these findings are discussed, and areas where further research is needed to better understand the molecular mechanisms and neuronal circuits underlying their neuropsychological effects are defined. Expand
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
TLDR
State-of-the art studies have recently begun to close important knowledge gaps by elucidating the mechanisms of action of psychedelics with regard to their effects on receptor subsystems, systems-level brain activity and connectivity, and cognitive and emotional processing. Expand
Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets
Abstract This chapter focuses on the potential use of serotonergic hallucinogen psilocybin in clinical as well as experimental psychiatry, addictology, and neurology. It presents the results ofExpand
Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
TLDR
Hypotheses derived from preclinical and human studies that need to be tested in future trials are presented to better understand the clinical potential of psychedelic substances in modern psychiatry. Expand
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
TLDR
The effects that psychedelic drugs have on certain structural and functional neuroendocrinological pathologies associated with neuropsychiatric disorders and cluster headache are reviewed and preliminary support for potential long-term effects is provided. Expand
Neurobiological Augmentation of Psychotherapy in Treatment Resistant
A substantial number of patients diagnosed with major depression disorder have poor or no response to standard antidepressive drugs. Recent studies showed that ketamine promotes a rapid and sustainedExpand
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
TLDR
This work aims to be a reference for psychiatrists who may soon be faced with the possibility of prescribing psychedelic compounds as medications, helping them assess which compound(s) and regimen could be most useful for decreasing specific psychiatric symptoms. Expand
Psychedelics and music: neuroscience and therapeutic implications
TLDR
The history of, contemporary research on, and future directions regarding the use of music in psychedelic research and therapy are explored, and more detailed and rigorous investigation of the contribution of music to the treatment of psychiatric disorders within the novel framework of psychedelic therapy is argued. Expand
Neurobiological Augmentation of Psychotherapy in Treatment Resistant Depression
A substantial number of patients diagnosed with major depression disorder have poor or no response to standard antidepressive drugs. Recent studies showed that ketamine promotes a rapid and sustainedExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 170 REFERENCES
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
TLDR
There is growing evidence that the glutamatergic system is central to the neurobiology and treatment of mood disorders and exciting new prospects for the development of improved therapeutics for these devastating disorders are discussed. Expand
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
TLDR
In considering neuroplasticity as a target for the treatment of psychiatric disorders, this review builds on exciting new findings in the areas of anxiety disorders, mood disorders, and schizophrenia. Expand
Serotonin research: contributions to understanding psychoses.
TLDR
Experimental assessments of the serotonergic hallucinogen model psychosis in relation to the serotonin hypothesis of schizophrenia are summarized. Expand
The experimental use of psychedelic (LSD) psychotherapy.
The history of research with psychedelic drugs has produced a variety of methods for their use and conflicting claims about results. First came the wave of excitement among experimentalists in theExpand
Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.
TLDR
The data demonstrate that the neuronal substrate of normal and abnormal thought and behavior is associated with a distributed neuronal network and with multiple interactive neurotransmitter systems, and support the view that the hallucinogen challenge paradigm constitutes a powerful tool for elucidating the pathophysiology of neuropsychiatric disorders. Expand
Neurocognitive mechanisms in depression: implications for treatment.
TLDR
Cognitive, neuroanatomical, and pharmacological tiers of research are drawn together to identify treatment targets and directions for future investigation to identify people at risk, minimize relapse, and maximize long-term beneficial outcomes for those suffering from depression. Expand
Antidepressant effects of ketamine in depressed patients
TLDR
A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression. Expand
Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action
TLDR
In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotics risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol. Expand
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
  • C. Large
  • Psychology, Medicine
  • Journal of psychopharmacology
  • 2007
TLDR
The extent to which the different hypotheses that have been proposed to account for the psychotomimetic effects of NMDA receptor antagonist have been validated by the results of these trials is considered. Expand
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
TLDR
Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model, and an agonist of this group of receptors attenuated the disruptive effects of Phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. Expand
...
1
2
3
4
5
...